Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis: exploratory analysis of 15-year data from the PRISMS study

被引：0
|
作者：
Kappos, L.
Uitdehaag, B.
Kuhle, J.
Issard, D.
Casset-Semanaz, F.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[3] Cytel Inc, Geneva, Switzerland
[4] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2013年 / 260卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O232
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [41] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [42] Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data
    Bell, CF
    Graham, JB
    Earnshaw, SR
    Oleen-Burkey, M
    Castelli-Haley, J
    Johnson, KP
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A81 - A82
  • [43] Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients
    London, F.
    El Sankari, S.
    van Pesch, V.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 133 - 133
  • [44] Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients
    London, Frederic
    El Sankari, Souraya
    van Pesch, Vincent
    [J]. CLINICAL NEUROPHYSIOLOGY, 2017, 128 (04) : 561 - 569
  • [45] Interferons in Relapsing-Remitting Multiple SclerosisAre There Benefits from Long-Term Use?
    Oscar Fernández
    [J]. CNS Drugs, 2004, 18 : 1057 - 1070
  • [46] Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
    Ziemssen, Tjalf
    Thomas, Katja
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (10) : 343 - 359
  • [47] Long-term follow-up of immunomodulatory therapies in early relapsing-remitting multiple sclerosis
    Haas, Judith
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S45 - S46
  • [48] Relation between acute exacerbations and long-term disability in patients with relapsing-remitting multiple sclerosis
    Gaillard, N
    Fabrot-Perray, R
    Lebayon, A
    Castelnovo, G
    Labauge, P
    [J]. MULTIPLE SCLEROSIS, 2005, 11 : S111 - S111
  • [49] Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis
    Castillo-Trivino, Tamara
    Gomez-Ballesteros, Rocio
    Borges, Monica
    Martin-Martinez, Jesils
    Sotoca, Javier
    Alonso, Ana
    Caminero Rodriguez, Ana Belen
    Borrega, Laura
    Sanchez-Menoyo, Jose Luis
    Barrero-Hernandez, Francisco
    Calles, Carmen
    Ruiz, Luis Brieva
    Blasco, Maria R.
    Garcia-Soto, Julio Dotor
    Del Campo-Amigo, Maria
    Navarro-Canto, Laura
    Morales, Eduardo Aguera
    Garces, Moises
    Codina, Olga Carmona
    Gabaldon-Torres, Laura
    Forero, Lucia
    Hervas, Mariona
    Maurino, Jorge
    de la Maza, Susana Sainz
    [J]. NEUROLOGY, 2022, 98 (18)
  • [50] Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence
    Khatri, Bhupendra O.
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (02) : 130 - 147
12345